ImmunoPrecise Antibodies Q3 EPS $(0.11) Misses $(0.07) Estimate, Sales $6.22M Beat $4.50M Estimate
Portfolio Pulse from Benzinga Newsdesk
ImmunoPrecise Antibodies reported its Q3 earnings with an EPS of $(0.11), missing the estimated $(0.07). However, its sales of $6.22M exceeded the $4.50M estimate.
March 14, 2024 | 12:17 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
ImmunoPrecise Antibodies reported a Q3 EPS of $(0.11), missing the $(0.07) estimate, but sales of $6.22M exceeded the $4.50M forecast.
The mixed Q3 earnings report from ImmunoPrecise Antibodies, with a miss on EPS but a beat on sales, presents a neutral short-term impact. The sales beat could offset concerns about the EPS miss, leading to a balanced market reaction.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100